Computed tomography imaging assessment of postexternal beam radiation changes of the liver.

Radiation is being used for patients with primary and secondary liver cancers, as a rapidly evolving treatment. However, postradiation imaging changes of the liver are not well understood and therefore challenging to interpret. Distinguishing normal radiation changes from residual or recurrent disease is difficult. Size and contrast enhancement have been used to guide interpretation and clinical recommendations, but normal radiation changes can make interpretation difficult and are not accounted for in available guidelines. Knowledge of dose- and time-dependent changes in addition to imaging findings, such as morphological and enhancement patterns, provides useful differentiating parameters. This paper reviews recent studies using computed tomography that can guide interpretation and help differentiate tumor from benign changes after external beam radiation.

[1]  B. Siewert,et al.  CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors , 2015, Gastroenterology research and practice.

[2]  C. Bassi,et al.  Prognostication and response assessment in liver and pancreatic tumors: The new imaging. , 2015, World journal of gastroenterology.

[3]  A. Kramar,et al.  Lobulated enhancement evaluation in the follow-up of liver metastases treated by stereotactic body radiation therapy. , 2015, International journal of radiation oncology, biology, physics.

[4]  L. Dawson,et al.  Localized and systemic approaches to treating hepatocellular carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. N. Kim,et al.  Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment , 2015, Expert review of gastroenterology & hepatology.

[6]  Zhe Chen,et al.  Motion management in gastrointestinal cancers. , 2014, Journal of gastrointestinal oncology.

[7]  The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation? , 2014, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[8]  S. Park,et al.  Stereotactic Body Radiotherapy-Induced Arterial Hypervascularity of Non-Tumorous Hepatic Parenchyma in Patients with Hepatocellular Carcinoma: Potential Pitfalls in Tumor Response Evaluation on Multiphase Computed Tomography , 2014, PloS one.

[9]  B. El-Rayes,et al.  Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. , 2014, Journal of vascular and interventional radiology : JVIR.

[10]  M. Abecassis,et al.  Radiological‐pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib , 2013, Hepatology.

[11]  A. Shuster,et al.  Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular c , 2013, Journal of vascular and interventional radiology : JVIR.

[12]  A. Kramar,et al.  Image-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory tracking , 2013, Radiation Oncology.

[13]  H. Geinitz,et al.  Radiotherapy in marginal zone lymphoma , 2013, Radiation oncology.

[14]  B. Kavanagh,et al.  Normal liver tissue density dose response in patients treated with stereotactic body radiation therapy for liver metastases. , 2012, International journal of radiation oncology, biology, physics.

[15]  Michael L Maitland,et al.  RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point. , 2012, Cancer research.

[16]  S. Perkins,et al.  Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma , 2012, Cancer.

[17]  P. Okunieff,et al.  An international survey on liver metastases radiotherapy , 2012, Acta oncologica.

[18]  Jacob D. Jaffe,et al.  Abstract 1: Oncogenic extracellular domain mutations of ERBB2 in cancer , 2012 .

[19]  Michael Lock,et al.  Radiotherapy for liver metastases: a review of evidence. , 2012, International journal of radiation oncology, biology, physics.

[20]  Y. Rolland,et al.  Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma , 2012, Cancer.

[21]  Tim Meyer,et al.  EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. , 2011, Journal of hepatology.

[22]  Katarzyna J Macura,et al.  Principles and applications of diffusion-weighted imaging in cancer detection, staging, and treatment follow-up. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[23]  James Ze Wang,et al.  Imaging changes after stereotactic body radiation therapy for lung and liver tumors , 2011, Expert review of anticancer therapy.

[24]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[25]  E. Kunieda,et al.  CT evaluations of focal liver reactions following stereotactic body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver function. , 2010, The British journal of radiology.

[26]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[27]  M. Abecassis,et al.  Radiologic–pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium‐90 microspheres , 2009, Hepatology.

[28]  M. McCarter,et al.  Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. , 2009, International journal of radiation oncology, biology, physics.

[29]  L. Gaspar,et al.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Jordi Rimola,et al.  Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma , 2009, Cancer.

[31]  W. Franklin,et al.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[33]  G. van Kaick,et al.  Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. , 2003, International journal of radiation oncology, biology, physics.

[34]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[35]  S. Chiou,et al.  The triple-phase CT image appearance of post-irradiated livers. , 2001, Acta radiologica.

[36]  S. Sourbron,et al.  Diffusion and perfusion MRI: basic physics. , 2001, European journal of radiology.

[37]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[38]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[39]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.